Fig 2: Temporal changes of IL-17A-expressing T cell subsets. (A) Representative dot plots showing the gating strategy for aortic IL-17A-expressing T cell subsets based on CXCR3 and IL-17RE from week 12 to week 18. (B) Representative dot plots showing the expression of CD200 and CCR4 in R3+RElow T cells and R3-REhigh T cells. (C) The proportions of aortic IL-17A-expressing T cells in total aortic cells. (D) The proportions of R3+RElow T cells and R3-REhigh T cells in aortic IL-17A-expressing T cells. (E) The proportions of 200+R4- and 200+R4+ cells in R3+RElow T cells at each time point. N = 5. *: p < .05. ***: p < .001.

Fig 3: The role of PI(4)P transport from Golgi to the PM in T-cell deterioration.a Model outlining the experimental design. b Expression of Foxp3 and CCR4 in T-cells infected with lentivirus carrying ORP4L or ORP4L(?OSBP) and cultured for 16 weeks. c Cell death analysis of T-cells as treated in (b). Black shapes present in dividual data points for n = 3 biological replicates (Data are presented as Mean ± SD). d Kaplan–Meier comparative survival analysis of B-NDG mice transplanted with T-cells as treated in (b), (n = 10 mice per group, Log-rank test). e Splenomegaly in B-NDG mice treated as in (d). The lower panel illustrates the organ weights. Scale bars, 1 cm. f The percentage of indicated cells analyzed from B-NDG mice treated as in (d). g Representative peripheral blood smear and H&E-staining of spleen and liver from B-NDG mice treated as in (d). Scale bars, 10 µm for blood smear, 100 µm for H&E. h Percentage of GFP+ transplanted ORP4L KI T-cells in peripheral blood of B-NDG mice after 10 days treatment with or without Dox. i Representative peripheral blood smears and H&E-staining of spleen and liver in B-NDG mice treated as in (h). Scale bars, 10 µm for blood smear, 100 µm for H&E. j Comparative survival analysis of B-NDG mice treated with or without Dox (n = 8 mice per group, Log-rank test). k A model outlining the functions of ORP4L and OSBP heterodimer in PI(4)P transport in ORP4L KI T-cells. Images of (g, i) are representative of n = 3 biological replicates with similar results. The same experiments were repeated twice in two mice. In panel of (e, f, h), black triangles present in dividual data points for n = 7 mice. In each box plot, the central mark indicates the median, the bottom and top edges of the box indicate the interquartile range, and the whiskers represent the maximum and minimum point. One-way ANOVA test with a confidence interval of 95% was used to compute statistics. P-values are indicated in the figures. Source data are provided as a Source Data file.

Fig 4: Phenotype of aortic IL-17A-expressing T cells. (A) Representative dot plots showing the gating strategy for aortic IL-17A-expressing T cell subsets based on CXCR3 and IL-17RE. (B) The proportions of R3+RElow T cells and R3-REhigh T cells in total aortic IL-17A-expressing T cells. (C) Representative dot plots showing the expression of CD200 and CCR4 in R3+RElow T cells and R3-REhigh T cells, respectively. (D) The proportions of 200+R4- and 200+R4+ cells in R3+RElow T cells, respectively. (E) Representative histograms showing ROR?t expression in indicated subsets. (F) Representative histograms showing T-bet protein in indicated subsets. (G) The mean fluorescence intensities (MFI) of T-bet in indicated subsets. (H) Representative dot plots showing intracellular staining of IFN-? in indicated subsets. (I) The proportions of IFN-?-expressing cells in indicated subsets. N = 3 or 5. ***: p < .001.

Fig 5: PLX3397 and aCSF1R reduce TAM-derived CCL22 that affect T cell recruitment. (A) 15 days after treatment began, serum of mice in each group was collected and the CBA method was used to detect Th1/Th2/Th17-related inflammatory factors, n = 10. (B) 15 days after treatment began, serum chemokine levels of CCL2, CCL22, CXCL10 and CXCL9 were detected by ELISA kit, n = 10. (C) Serum levels of CCL22 at day 0,5,10,15 and 20 during the development of murine subcutaneous tumors, with treatment starting at day 7 after tumor inoculation, n = 10. (D) Macrophages, T cells and CD45- cells within the tumor on 9DPT and 15 DPT were sorted and the overall transcription levels of these cells were analyzed. (E) Representative flow cytometry histogram of CCR4 levels in Treg in tumor of LLC subcutaneous tumor model. (F) CD8T/Treg ratio at 13 DPT treated with CCL22 combined with PLX3397; And (G) tumor volume changes in during the treatment, n = 10.